Chiara Fulcheri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chiara Fulcheri has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Franco Veglio
Division of Internal Medicine, Hypertension Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza, Via Genova 3, 10126, Turin, Italy
4 shared publicationsElena Berra
University of Torino
3 shared publicationsFranco Rabbia
Division of Internal Medicine, Hypertension Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza, Via Genova 3, 10126, Turin, Italy
3 shared publications- Franco Rabbia
University of Turin
3 shared publications - Marco Pappaccogli
Division of Internal Medicine and Hypertension Unit, Department of Medical Sciences, University of Turin, Turin, Italy
2 shared publications Michele Covella
University of Torino
2 shared publications
Latest Publications
- 26 February 2019
- Published by Springer Nature in High Blood Pressure & Cardiovascular Prevention
- Vol. 26 (2) , 143-144
Trisomy of the Short Arm of Chromosome 12 Associated with High Cardiovascular Risk: A Case Report
Trisomy of the short arm of chromosome 12 is a rare genetic disease characterised by dysmorphic features, mental retardation, behavioural disorders, seizures predisposition and other congenital abnormalities. Arterial hypertension is not a characteristic feature of 12p trisomy, although congenital heart defects are reported. In this case report, we present a young patient with incomplete trisomy 12p, analysing some characteristics of this disease that have not been previously described in literature.
- 26 February 2019
- Published by Springer Nature in High Blood Pressure & Cardiovascular Prevention
- Vol. 26 (2) , 143-144
Trisomy of the Short Arm of Chromosome 12 Associated with High Cardiovascular Risk: A Case Report
Trisomy of the short arm of chromosome 12 is a rare genetic disease characterised by dysmorphic features, mental retardation, behavioural disorders, seizures predisposition and other congenital abnormalities. Arterial hypertension is not a characteristic feature of 12p trisomy, although congenital heart defects are reported. In this case report, we present a young patient with incomplete trisomy 12p, analysing some characteristics of this disease that have not been previously described in literature.
- 3 April 2017
- Published by Springer Nature in High Blood Pressure & Cardiovascular Prevention
- Vol. 24 (2) , 187-192
Procedural Reassessment of Radiofrequency Renal Denervation in Resistant Hypertensive Patients
- 3 April 2017
- Published by Springer Nature in High Blood Pressure & Cardiovascular Prevention
- Vol. 24 (2) , 187-192
Procedural Reassessment of Radiofrequency Renal Denervation in Resistant Hypertensive Patients
- 9 May 2016
- Published by Springer Nature in High Blood Pressure & Cardiovascular Prevention
- Vol. 23 (4) , 341-345
Adherence to antihypertensive therapy and therapeutic dosage of antihypertensive drugs
Adherence to antihypertensive therapy is critical to achieving adequate blood pressure control. About half of hypertensive patients do not take their drugs as directed and the physicians often underestimate this issue. Non-adherence has important public health economic implications (numbers of visits, diagnostic procedures, prescribed drugs) and, moreover, it results in increased morbidity and mortality rates. Poor adherence can have several patients and therapy related causes. Currently, multiple different direct and indirect methods to measure therapeutic adherence are available, but, in clinical practice, there is no cost-effective and simple one. Therapeutic drug monitoring (TDM), characterized by drug (or metabolites) concentration measurement in body fluids (blood or urine), is a cost-effective direct method to assess therapeutic adherence. Despite some limitations, TDM may decrease health costs, by reducing the number of visits and by identifying those patients who would undergo unnecessary invasive procedures. Moreover, TDM can be a new alternative method to identify patients with true resistant hypertension, improving the achievement of blood pressure control In this minor revision, we would assess poor therapeutic adherence in hypertensive population, analyzing the different direct and direct available methods, with emphasis on TDM.
- 9 May 2016
- Published by Springer Nature in High Blood Pressure & Cardiovascular Prevention
- Vol. 23 (4) , 341-345
Adherence to antihypertensive therapy and therapeutic dosage of antihypertensive drugs
Adherence to antihypertensive therapy is critical to achieving adequate blood pressure control. About half of hypertensive patients do not take their drugs as directed and the physicians often underestimate this issue. Non-adherence has important public health economic implications (numbers of visits, diagnostic procedures, prescribed drugs) and, moreover, it results in increased morbidity and mortality rates. Poor adherence can have several patients and therapy related causes. Currently, multiple different direct and indirect methods to measure therapeutic adherence are available, but, in clinical practice, there is no cost-effective and simple one. Therapeutic drug monitoring (TDM), characterized by drug (or metabolites) concentration measurement in body fluids (blood or urine), is a cost-effective direct method to assess therapeutic adherence. Despite some limitations, TDM may decrease health costs, by reducing the number of visits and by identifying those patients who would undergo unnecessary invasive procedures. Moreover, TDM can be a new alternative method to identify patients with true resistant hypertension, improving the achievement of blood pressure control In this minor revision, we would assess poor therapeutic adherence in hypertensive population, analyzing the different direct and direct available methods, with emphasis on TDM.
- 1 March 2016
- Published by Wolters Kluwer Health in Hypertension
- Vol. 67 (3) , e3-4
Antihypertensive Bridge Therapy by Continuous Drug Infusion With an Elastomeric Pump in Device-Resistant Hypertension
- 1 March 2016
- Published by Wolters Kluwer Health in Hypertension
- Vol. 67 (3) , e3-4
Antihypertensive Bridge Therapy by Continuous Drug Infusion With an Elastomeric Pump in Device-Resistant Hypertension
- 1 December 2015
- Published by Elsevier in Annales de Cardiologie et d'Angéiologie
- Vol. 64, S84
P-182: Analysis of eligibility criteria for renal sympathetic denervation in patients with resistant hypertension
- 1 December 2015
- Published by Elsevier in Annales de Cardiologie et d'Angéiologie
- Vol. 64, S84
P-182: Analysis of eligibility criteria for renal sympathetic denervation in patients with resistant hypertension
- 9 July 2012
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 14 (10) , 729-730
Appropriateness of Referral to a European Society of Hypertension Center of Excellence
- 9 July 2012
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 14 (10) , 729-730
Appropriateness of Referral to a European Society of Hypertension Center of Excellence